Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Mindset Pharma Inc.
  6. News
  7. Summary
    MSET   CA60268M1023

MINDSET PHARMA INC.

(MSET)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

07/07/2021 | 07:30am EDT

Mindset Pharma Inc. announced that its first lead clinical candidate, MSP-1014, a differentiated next-generation psilocybin drug candidate from its Family 1 of novel, patent-pending psychedelic compounds, has further demonstrated superior efficacy and an improved safety profile in head-to-head pre-clinical comparisons to psilocybin. MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSP-1014 was the first compound identified by the Company to progress towards human clinical trials after displaying high rates of success through a comprehensive range of specialized in vitro and in vivo tests.


ę S&P Capital IQ 2021
All news about MINDSET PHARMA INC.
09/20Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and ..
GL
09/14MINDSET PHARMA : Further Validates Lead Candidate as Next Generation Psilocybin Analog Thr..
MT
09/14MINDSET PHARMA : Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocyb..
AQ
09/09Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as I..
GL
09/07Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its ..
GL
09/07Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its ..
CI
09/02MINDSET PHARMA : to Participate in Upcoming Investor Conferences in September 2021
AQ
08/31Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demons..
GL
08/31Mindset Pharma Inc. Announces Next Generation Novel 5-Meo-Dmt Psychedelic Analogs Demon..
CI
08/26MINDSET PHARMA : Announces Preclinical Results Demonstrating Extended Duration of Action i..
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -0,64 M -0,50 M -0,50 M
Net cash 2020 0,54 M 0,42 M 0,42 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 73,0 M 57,0 M 57,0 M
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees -
Free-Float -
Chart MINDSET PHARMA INC.
Duration : Period :
Mindset Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
James Andre Charles Lanthier Chief Executive Officer
Arvin Ramos Chief Financial Officer
Richard J. Patricio Chairman
Joseph Araujo Director & Chief Science Officer
James Christopher Passin Director
Sector and Competitors
1st jan.Capi. (M$)
MINDSET PHARMA INC.-10.64%57
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021